von der Weid N, Wagner B, Baumgartner C, Beck D, Bertrand A M, Bleher E A, Caflisch U, Delaleu B, Feldges A, Frei H
Swiss Pediatric Oncology Group, Institute for Clinical and Experimental Cancer Research, Berne.
Helv Paediatr Acta. 1987 Jun;42(5-6):363-70.
Of 45 children with ALL who had a first hematological recurrence between 1981 and 1984, 33 relapsed while still on treatment and 12 after cessation of therapy. Of the former 1 of 16 high risk (initial WBC greater than or equal to 20 x 10(9)/l and/or enlargement of the mediastinum) and 5 of 17 low risk patients (initial WBC less than 20 x 10(9)/l and no enlargement of the mediastinum), of the latter 6 patients survived after a minimum follow-up of 20 months. During the same time period, a first isolated CNS relapse was observed in 24 children of whom 16 survived. These results suggest that at the time of evaluation 1. the prognosis of children with ALL in first hematological relapse during the years 1981-1984 was not significantly different from that of similar children treated earlier; and 2. the prognosis of children with isolated CNS relapse had improved.
在1981年至1984年间首次出现血液学复发的45例急性淋巴细胞白血病（ALL）患儿中，33例在仍接受治疗时复发，12例在治疗停止后复发。在前者中，16例高危患者（初始白细胞计数大于或等于20×10⁹/L和/或纵隔增宽）中有1例复发，17例低危患者（初始白细胞计数小于20×10⁹/L且无纵隔增宽）中有5例复发；在后者中，6例患者在至少随访20个月后存活。在同一时期，24例患儿出现首次孤立性中枢神经系统复发，其中16例存活。这些结果表明，在评估时：1. 1981 - 1984年间首次出现血液学复发的ALL患儿的预后与早期治疗的类似患儿相比无显著差异；2. 孤立性中枢神经系统复发患儿的预后有所改善。
